- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05687500
Glibenclamida Oral na Hiperglicemia Prematura (GALOP) (GALOP)
The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.
Visão geral do estudo
Status
Descrição detalhada
Transient hyperglycemia of premature newborns results from an overall decrease in insulin sensitivity, which is responsible at the beta cell level for abnormalities of intragranular cleavage of proinsulin into insulin, leading to reduced active insulin secretion. Intravenous administration of exogenous insulin can be used to combat insulin resistance and lower blood glucose, but it is difficult to manage in premature newborns and is associated with a substantial risk of hypoglycemia. Glibenclamide, which stimulates endogenous insulin secretion and can be administered orally, might be an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Paris, França, 75015
- Hopital Necker - Enfants malades
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Newborn less than 34 week of amenorrhea corrected age
- Birth weight < 1500 g
- Birth term < 32 week of amenorrhea
- Hyperglycemia ≥ 10 mmol/l in 2 measurements, 3 hours apart after potential reduction of glucose intakes following each department's protocol
- Secure venous access point (umbilical venous catheter or epicutaneo-cava catheter)
- Enteral feeding considered before inclusion or already established
- Consent obtained from persons holding parental authority
- Beneficiary of social security
Exclusion Criteria
- Contraindication to enteral feeding (at the discretion of the clinician responsible for the child)
- Contraindication to glibenclamide according to current SPC
- Foetal growth restriction (FGR) birth weight < 3rd percentile (AUDIPOG definition)
- Severe birth defect, including cardiac malformation associated with a risk of myocardial ischemia
- Severe sepsis requiring mechanical ventilation or haemodynamic support
- Severe renal dysfunction (serum creatinine > 120 µmol/l)
- Severe hepatocellular failure (V factor less than the standard laboratory range for the age) and/or severe cholestasis (> 50 µmol/L)
- Hyperglycemia associated with an error in administering glucose infusion
- Profound hypophosphoremia (< 1 mmol/l)
- Hypersensitivity to glibenclamide or other sulphonylureas or sulphonamides, or one of the excipients
- Patient with continuous insulin IV administration
- Patient treated with miconazole
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Glibenclamide oral
Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk |
Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant, apparent clearance and volume of distribution. blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio if it is impossible to collect both volumes, the C-peptide collection will be prioritized If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram, total bilirubin and conjugated bilirubin will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment. Transaminases and hemostasis will be done only in case of clinical indication before the first administration. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Blood glucose control
Prazo: At 72 hours after the first administration
|
The primary evaluation criteria is 72 hours blood glucose control on glibenclamide treatment (success of the treatment). This is defined as the non-use of insulin and absence of severe hypoglycemia (< 1.5 mmol/l) or persistent moderate hypoglycemia (< 2.6 mmol/l in 2 successive measurements (dextro) at an interval of more than 3 hours) |
At 72 hours after the first administration
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall success of the treatment
Prazo: At 36 week of amenorrhea corrected age
|
Overall success of the treatment defined by continuation to the end of treatment without recourse to insulin. |
At 36 week of amenorrhea corrected age
|
|
Blood glucose profile on glibenclamide
Prazo: At the end of treatment assessed up to 15 days
|
Time between the start of glibenclamide treatment and the 1st blood glucose < 10 mmol/l |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
Prazo: At the end of treatment assessed up to 15 days
|
Time between the start of glibenclamide treatment and the 1st blood glucose < 8 mmol/l |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
Prazo: At the end of treatment assessed up to 15 days
|
Proportion of time spent within the target blood glucose range (≥ 4 and < 10 mmol/l) during the period of glibenclamide treatment |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
Prazo: At the end of treatment assessed up to 15 days
|
Proportion of time spent above the target level (≥ 10 mmol/l) during the period of glibenclamide treatment |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
Prazo: At the end of treatment assessed up to 15 days
|
Proportion of time spent in hypoglycemia (< 2.6 mmol/l) during the period of glibenclamide treatment |
At the end of treatment assessed up to 15 days
|
|
Duration of glibenclamide treatment
Prazo: At the end of treatment assessed up to 15 days
|
Duration of glibenclamide treatment. |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth
Prazo: At the end of treatment assessed up to 15 days
|
Carbohydrate |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
Prazo: At the end of treatment assessed up to 15 days
|
lipid |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
Prazo: At the end of treatment assessed up to 15 days
|
protein |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
Prazo: At the end of treatment assessed up to 15 days
|
mean caloric intake (kcal/kg/day) during treatment |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
Prazo: At the end of treatment assessed up to 15 days
|
mean weight gain (g/kg/day) |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth
Prazo: At 36 week of amenorrhea corrected age
|
Carbohydrate |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
Prazo: At 36 week of amenorrhea corrected age
|
lipid |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
Prazo: At 36 week of amenorrhea corrected age
|
protein |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
Prazo: At 36 week of amenorrhea corrected age
|
mean caloric intake (kcal/kg/day) during treatment |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
Prazo: At 36 week of amenorrhea corrected age
|
mean weight gain ((g/kg/day) |
At 36 week of amenorrhea corrected age
|
|
Number of children with episode of hypoglycemia
Prazo: At 72 hours after first administration
|
Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia |
At 72 hours after first administration
|
|
Number of children with episode of hypoglycemia
Prazo: At the end of treatment assessed up to 15 days
|
Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia |
At the end of treatment assessed up to 15 days
|
|
Type of adverse reactions on glibenclamide
Prazo: At 36 week of amenorrhea corrected age
|
evaluation of the type of adverse reactions identified during the study |
At 36 week of amenorrhea corrected age
|
|
Number of adverse reactions on glibenclamide
Prazo: At 36 week of amenorrhea corrected age
|
evaluation of number of adverse reactions identified during the study |
At 36 week of amenorrhea corrected age
|
|
Number of participants with co-morbidity
Prazo: At 36 week of amenorrhea corrected age
|
Neonatal morbidity assessed at 36 WA corrected age: intraventricular haemorrhage, periventricular leukomalacia, retinopathy of premature newborns, haemodynamic disorders, ulcerative necrotising enterocolitis |
At 36 week of amenorrhea corrected age
|
|
Mortality
Prazo: At 36 week of amenorrhea corrected age
|
Mortality will be assessed |
At 36 week of amenorrhea corrected age
|
|
Dose adjustment
Prazo: At the end of treatment assessed up to 15 days
|
Number of dose adjustments, to evaluate the easy of use |
At the end of treatment assessed up to 15 days
|
|
ease of use by caregivers
Prazo: At day one of treatment
|
Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score |
At day one of treatment
|
|
ease of use by caregivers
Prazo: At day two of treatment
|
Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score |
At day two of treatment
|
|
ease of use by caregivers
Prazo: At day three of treatment
|
Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score |
At day three of treatment
|
|
Plasma concentrations of glibenclamide
Prazo: At 3 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 3 hours after the first administration
|
|
Plasma concentrations of glibenclamide
Prazo: At 6 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 6 hours after the first administration
|
|
Plasma concentrations of glibenclamide
Prazo: At 10 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 10 hours after the first administration
|
|
Plasma concentrations of glibenclamide
Prazo: At 24 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 24 hours after the first administration
|
|
Plasma concentrations of glibenclamide
Prazo: At 24 hours of blood glucose stabilization
|
Evaluated by the pharmacokinetics study |
At 24 hours of blood glucose stabilization
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Jacques BELTRAND, Pr, Assistance Publique - Hôpitaux de Paris
- Diretor de estudo: Michel POLAK, Assistance Publique - Hôpitaux de Paris
- Diretor de estudo: Delphine MITANCHEZ, CHRU de Tours
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças urogenitais femininas e complicações na gravidez
- Doenças Metabólicas
- Trabalho de parto prematuro
- Complicações do Trabalho de Parto Obstétrico
- Complicações na Gravidez
- Distúrbios do Metabolismo da Glicose
- Doenças Nutricionais e Metabólicas
- Nascimento prematuro
- Hipoglicemia
- Compostos de enxofre
- Produtos químicos orgânicos
- Amidas
- Sulfonas
- Uréia
- Compostos de sulfonilureia
- Gliburida
Outros números de identificação do estudo
- P160916J
- 2021-005766-18 (Número EudraCT)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .